In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Dexcom (DXCM – Research Report), with a price target of $145.00. The company’s shares closed yesterday at $133.04.
Biegelsen covers the Healthcare sector, focusing on stocks such as Abbott Labs, Bausch + Lomb Corporation, and Boston Scientific. According to TipRanks, Biegelsen has an average return of 12.3% and a 62.61% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dexcom with a $152.00 average price target, implying a 14.25% upside from current levels. In a report released today, RBC Capital also initiated coverage with a Buy rating on the stock with a $165.00 price target.
See the top stocks recommended by analysts >>
DXCM market cap is currently $52.14B and has a P/E ratio of 101.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dexcom (DXCM) Company Description:
California-based DexCom, Inc. is a medical device manufacturing company. The company designs, develops and focuses on commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes. Its products include DexCom G4 PLATINUM System, DexCom G5 Mobil, DexCom G6, and DexCom Share.
Read More on DXCM:
- Early notable gainers among liquid option names on March 6th
- DexCom’s (NASDAQ:DXCM) Stelo Becomes First Glucose Monitor Cleared for OTC Use
- DexCom announces FDA clears Stelo biosensor
- DexCom announces new CGM data, direct to Apple Watch functionality in Q2
- DexCom call volume above normal and directionally bullish
